Merck: positive data in urothelial carcinoma
(CercleFinance.com) - Merck announces that a Phase III trial evaluating Keytruda has met one of its two primary endpoints - disease-free survival - in selected patients with muscle-invasive urothelial carcinoma (MIUC) following surgery.
In a pre-specified interim analysis conducted by an independent committee, the drug demonstrated a statistically and clinically significant improvement in disease-free survival, compared with observation in these patients after surgery.
The trial will continue to evaluate its other primary endpoint, i.e. overall survival. The safety profile was consistent with that observed previously. Results will be discussed with regulatory authorities.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
In a pre-specified interim analysis conducted by an independent committee, the drug demonstrated a statistically and clinically significant improvement in disease-free survival, compared with observation in these patients after surgery.
The trial will continue to evaluate its other primary endpoint, i.e. overall survival. The safety profile was consistent with that observed previously. Results will be discussed with regulatory authorities.
Copyright (c) 2023 CercleFinance.com. All rights reserved.